Entrada Therapeutics (TRDA) Enterprise Value (2020 - 2026)

Entrada Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$76.4 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 12.69% year-over-year to -$76.4 million in Q1 2026; TTM through Mar 2026 was -$76.4 million, a 12.69% decrease from a year earlier, with the FY2025 full-year figure at -$91.1 million, up 10.04% from the prior year.
• Enterprise Value advanced to -$76.4 million in Q1 2026 per TRDA's latest filing, from -$91.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$45.2 million in Q4 2022 and bottomed at -$263.9 million in Q1 2022.
• The 5-year median for Enterprise Value is -$79.7 million (2023), against an average of -$119.4 million.
• Across the five-year window, Enterprise Value surged 84.49% in 2022 and sank 132.31% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$45.2 million in 2022, then sank by 49.7% to -$67.6 million in 2023, then tumbled by 49.72% to -$101.2 million in 2024, then gained by 10.04% to -$91.1 million in 2025, then advanced by 16.04% to -$76.4 million in 2026.
• Per Business Quant, the three latest TRDA Enterprise Value figures stand at -$76.4 million (Q1 2026), -$91.1 million (Q4 2025), and -$93.3 million (Q3 2025).